Therapy Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Therapy Name Busulfan + Melphalan
Synonyms
Therapy Description

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Busulfan Busulfex Busulphan Busulfex (busulfan) inhibits DNA replication and RNA transcription, likely through induction of DNA alkylation (PMID: 27481448). Busulfex (busulfan) in combination with cyclophosphamide is FDA approved as a conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation for patients with chronic myelogenous leukemia (FDA.gov).
Melphalan Alkeran Chemotherapy - Alkylating 18 Alkeran (melphalan) is an antineoplastic alkylating agent, which cross-links DNA and induces cell toxicity and is FDA approved for multiple myeloma and epithelial ovarian carcinoma (FDA.gov).

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT00084695 Phase II Fludarabine Busulfan + Melphalan anti-thymocyte globulin Cyclophosphamide Prednisone Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases Unknown status USA 0
NCT01175356 Phase I Busulfan + Melphalan Cyclophosphamide + Topotecan 131I-MIBG Cyclophosphamide + Doxorubicin + Vincristine Sulfate Cisplatin + Etoposide Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin Active, not recruiting USA 0
NCT01704716 Phase III Busulfan + Melphalan Carboplatin + Cisplatin + Cyclophosphamide + Etoposide + Filgrastim Cisplatin + Cyclophosphamide + Doxorubicin + Etoposide + Vincristine Sulfate Dinutuximab beta Aldesleukin + Dinutuximab beta Carboplatin + Etoposide + Melphalan Carboplatin + Cisplatin + Cyclophosphamide + Etoposide + Vincristine Sulfate High Risk Neuroblastoma Study 1.8 of SIOP-Europe (SIOPEN) Recruiting SWE | SVN | SVK | POL | NOR | ITA | ISR | IRL | HUN | GRC | GBR | FRA | ESP | DNK | CZE | CHE | BEL | AUT | AUS 1
NCT02589145 Phase Ib/II Lenalidomide Pyridoxine Dexamethasone Busulfan + Melphalan Enoxaparin Rituximab Gemcitabine Vorinostat Palifermin Lenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC Subtype Terminated USA 0
NCT01983969 Phase Ib/II Rituximab Dexamethasone Busulfan + Melphalan Azacitidine + Gemcitabine + Vorinostat Aza-SAHA-GBM With AutoSCT for Refractory Lymphoma Completed USA 0
NCT02506959 Phase II Dexamethasone Busulfan + Melphalan Pyridoxine Panobinostat Palifermin Gemcitabine Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Myeloma Completed USA 0
NCT00020566 Phase III Busulfan + Melphalan Dactinomycin + Doxorubicin + Etoposide + Ifosfamide + Vincristine Sulfate Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation, Radiation Therapy, and/or Surgery in Treating Patients With Ewing's Sarcoma Unknown status USA | NZL | CAN | AUS 1
NCT01857934 Phase II Doxorubicin Sargramostim Aldesleukin Vincristine Sulfate Filgrastim Tretinoin Levetiracetam Cisplatin + Etoposide Hu14.18K322A Busulfan + Melphalan Cyclophosphamide + Topotecan Therapy for Children With Advanced Stage Neuroblastoma Active, not recruiting USA 0
NCT01505569 Phase I Filgrastim Busulfan + Melphalan Etoposide + Ifosfamide Thiotepa Carboplatin Auto Transplant for High Risk or Relapsed Solid or CNS Tumors Completed USA 0
NCT04221035 Phase III Busulfan + Melphalan + Thiotepa Dinutuximab beta Cisplatin + Etoposide + Vindesine Dacarbazine + Doxorubicin + Ifosfamide + Vincristine Sulfate Carboplatin + Cisplatin + Cyclophosphamide + Etoposide + Vincristine Sulfate Busulfan + Melphalan High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN) (HR-NBL2) Recruiting SWE | SVN | SVK | NOR | NLD | LTU | ITA | ISR | GRC | GBR | FRA | FIN | ESP | DNK | DEU | CZE | CHE | BEL | AUS 0
NCT05830084 Phase I Cyclophosphamide + Etoposide + Ifosfamide + Regorafenib + Vincristine Sulfate Cyclophosphamide + Doxorubicin + Etoposide + Ifosfamide + Regorafenib + Vincristine Sulfate Busulfan + Melphalan Phase Ib / Regorafenib With Conventional Chemotherapy/Newly Diagnosed Patients/ Multimetastatic Ewing Sarcoma (REGO-EWING) Recruiting FRA 0


Additional content available in CKB BOOST